#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	19458	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2533	937.2	0	.	n	.	0	A69G	SNP	69	69	A	615	615	G	1203	G,A,C	869,331,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	19458	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2533	937.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1996	1996	T	1194	T,G,A	1190,3,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	19458	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2533	937.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1730	1730	C	1283	C	1282	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	19458	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2533	937.2	0	HET	.	.	.	C260T,A	.	260	260	C	806	806	C	1113	C,T,A	848,264,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32774	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4068	1004.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1953	1953	A	1340	A,G	1338,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32774	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4068	1004.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2587	2587	C	1146	C,A	1145,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32774	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4068	1004.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2661	2661	A	1046	A	1046	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32774	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4068	1004.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3213	3213	C	1180	C,T,A	1177,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	2940	folP	852	852	99.88	folP.l15.c4.ctg.1	2009	182.4	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1055	1057	AAA	309;308;307	A;A;A	309;308;307	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	2940	folP	852	852	99.88	folP.l15.c4.ctg.1	2009	182.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1286	1288	AGC	298;300;302	A,C;G;C,G	297,1;300;301,1	folP.WHO_M_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	7676	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3806	251.3	1	SNP	p	S91F	0	.	.	271	273	TCC	758	760	TCC	275;277;277	T,G;C,A;C,A	274,1;276,1;276,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	7676	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3806	251.3	1	SNP	p	D95N	0	.	.	283	285	GAC	770	772	GAC	303;306;308	G,T;A,C;C	302,1;305,1;308	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	7676	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3806	251.3	1	SNP	p	D95G	0	.	.	283	285	GAC	770	772	GAC	303;306;308	G,T;A,C;C	302,1;305,1;308	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	2780	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1725	201.0	1	SNP	p	G45D	0	.	.	133	135	GGC	664	666	GGC	349;347;346	G;G;C	349;347;346	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1468	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1445	126.6	0	.	n	.	0	A197.	DEL	197	197	A	782	782	A	281	A	281	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6680	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3400	245.1	1	SNP	p	D86N	0	.	.	256	258	GAC	823	825	GAC	311;311;310	G;A,G;C	311;309,2;310	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6680	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3400	245.1	1	SNP	p	S87I	0	.	.	259	261	AGT	826	828	AGT	309;309;309	A;G;T	309;309;309	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6680	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3400	245.1	1	SNP	p	S87W	0	.	.	259	261	AGT	826	828	AGT	309;309;309	A;G;T	309;309;309	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6680	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3400	245.1	1	SNP	p	S87R	0	.	.	259	261	AGT	826	828	AGT	309;309;309	A;G;T	309;309;309	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6680	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3400	245.1	1	SNP	p	S88P	0	.	.	262	264	TCC	829	831	TCC	308;308;308	T,G;C;C,T	307,1;308;307,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5918	parE	1986	1986	100.0	parE.l6.c17.ctg.1	3258	226.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1930	1932	GGC	317;314;307	G;G,T,A;C,T	317;312,1,1;306,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	5544	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2831	244.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1502	1504	GCA	308;309;306	G,A,C;C;A	306,1,1;309;306	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5544	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2831	244.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1505	1507	ATC	309;310;309	A;T,G;C	309;308,2;309	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5544	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2831	244.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1517	1519	GTG	291;293;293	G,T;T,C;G,T,A	289,2;292,1;291,1,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5544	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2831	244.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1517	1519	GTG	291;293;293	G,T;T,C;G,T,A	289,2;292,1;291,1,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5544	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2831	244.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2021	2023	ACC	312;316;318	A;C,G;C,T	312;314,2;317,1	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5544	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2831	244.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2075	2077	GCG	311;315;313	G,T;C,T,A;G,T	310,1;313,1,1;312,1	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5544	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2831	244.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2075	2077	GCG	311;315;313	G,T;C,T,A;G,T	310,1;313,1,1;312,1	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5544	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2831	244.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2198	2200	GGC	326;326;327	G;G,T;C,T	326;325,1;326,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5544	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2831	244.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2207	2209	GGC	323;324;325	G,T;G;C	322,1;324;325	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5544	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2831	244.3	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2225	2227	CTG	329;327;325	C;T,G;G	329;326,1;325	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	7268	ponA	2397	2397	100.0	ponA.l15.c17.ctg.1	3350	269.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1729	1731	CCG	291;290;288	C;C;G,T,C	291;290;286,1,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3408	porA	1146	1146	99.65	porA.l15.c17.ctg.1	2217	191.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	748	748	C	250	C,G	249,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	412	porB1a	984	93	94.62	porB1a.l15.c30.ctg.1	177	78.8	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	91;87;82	A;C;G	91;87;82	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	412	porB1a	984	222	90.54	porB1a.l15.c30.ctg.2	353	35.8	0	.	p	.	0	V258L	NONSYN	772	774	GTA	13	15	TTA	35;40;42	T;T;A	35;40;42	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	412	porB1a	984	222	90.54	porB1a.l15.c30.ctg.2	353	35.8	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	58	60	CAT	80;80;80	C;A;T	80;80;80	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	412	porB1a	984	222	90.54	porB1a.l15.c30.ctg.2	353	35.8	0	.	p	.	0	D274S	NONSYN	820	822	GAT	61	63	AGT	80;80;80	A;G;T	80;80;80	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	412	porB1a	984	222	90.54	porB1a.l15.c30.ctg.2	353	35.8	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	70	72	TAC	80;80;80	T;A;C	80;80;80	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	412	porB1a	984	222	90.54	porB1a.l15.c30.ctg.2	353	35.8	0	.	p	.	0	R307V	NONSYN	919	921	AGA	160	162	GTA	3;3;3	G;T;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	412	porB1a	984	222	90.54	porB1a.l15.c30.ctg.2	353	35.8	0	.	p	.	0	T311A	NONSYN	931	933	ACA	172	174	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	412	porB1a	984	222	90.54	porB1a.l15.c30.ctg.2	353	35.8	0	.	p	.	0	E312D	NONSYN	934	936	GAA	175	177	GAC	3;3;3	G;A;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	412	porB1a	984	222	90.54	porB1a.l15.c30.ctg.2	353	35.8	0	.	p	.	0	F314I	NONSYN	940	942	TTC	181	183	ATC	3;3;3	A;T;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	412	porB1a	984	222	90.54	porB1a.l15.c30.ctg.2	353	35.8	0	.	p	.	0	A316S	NONSYN	946	948	GCG	187	189	TCG	3;3;3	T;C;G	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	412	porB1a	984	222	90.54	porB1a.l15.c30.ctg.2	353	35.8	0	.	p	.	0	V318A	NONSYN	952	954	GTC	193	195	GCC	5;5;5	G;C;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	412	porB1a	984	222	90.54	porB1a.l15.c30.ctg.2	353	35.8	0	.	p	.	0	G319S	NONSYN	955	957	GGC	196	198	AGC	5;5;5	A;G;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	412	porB1a	984	222	90.54	porB1a.l15.c30.ctg.2	353	35.8	0	.	p	.	0	G320A	NONSYN	958	960	GGT	199	201	GCC	5;5;4	G;C;C	5;5;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	412	porB1a	984	222	90.54	porB1a.l15.c30.ctg.2	353	35.8	0	.	p	.	0	G322V	NONSYN	964	966	GGT	205	207	GTT	4;4;4	G;T;T	4;4;4	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3898	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1982	244.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	678	680	GAA	333;337;336	G;A;A,G	333;336;334,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3898	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1982	244.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	966	968	GAT	320;319;323	G;A,G;T,A	320;318,1;322,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3898	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1982	244.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1089	1091	TCA	339;342;346	T;C;A	339;342;346	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3898	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1982	244.5	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1218	1220	GTC	343;343;341	G;T;C	343;343;341	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3898	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1982	244.5	0	.	p	.	0	E328V	NONSYN	982	984	GAA	1548	1550	GTA	282;283;285	G;T,G;A,C	282;282,1;284,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3898	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1982	244.5	1	SNP	p	G120K	1	.	.	358	360	AAG	924	926	AAG	354;353;350	A,C;A,C;G,T	353,1;352,1;348,2	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3898	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1982	244.5	1	SNP	p	A121D	1	.	.	361	363	GAC	927	929	GAC	348;347;351	G;A,C;C	348;346,1;351	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3898	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1982	244.5	1	SNP	p	D121N	0	.	.	361	363	GAC	927	929	GAC	348;347;351	G;A,C;C	348;346,1;351	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	12534	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5281	295.9	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2184	2186	AAT	380;379;377	A;A;T,G	380;379;376,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1820	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1387	163.1	1	SNP	p	V57M	1	.	.	169	171	ATG	698	700	ATG	290;294;295	A;T;G	290;294;295	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
